Celltrion looks beyond biosimilars with $744M pact for 2 preclinical autoimmune drugs
Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune assets from U.S. biotech Kaigene. One of the antibodies, dubbed KG006, is…